Celyad receives FDA fast-track status for C-Cure to treat ischemic heart failure

Belgian biopharmaceutical firm Celyad has secured fast-track designation from the US Food and Drug Administration (FDA) for its C-Cure ® therapy for patients with chronic heart failure, secondary to ischemic cardiomyopathy with baseline Left Ventricul …
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news